Telomir Pharmaceuticals Inc Dossier - Source-backed chat

Telomir Pharmaceuticals Inc

TELONASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.17

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.20Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $82.5M

Enterprise Value $81.9M

Shares Outstanding 68.8M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Telomir Pharmaceuticals is a preclinical-to-clinical transition stage biotechnology company developing Telomir-1 (Telomir-Zn), a first-in-class small molecule designed to regulate metal ions and address epigenetic drivers of cancer and age-related diseases. The company achieved a major milestone in April 2026 by securing FDA IND clearance for Telomir-Zn in advanced and metastatic Triple-Negative Breast Cancer (TNBC). While this transitions the company into a clinical-stage operator, Telomir remains pre-revenue with a high cash burn rate and a cash runway extending only into Q1 2027. Given the early stage of clinical development and the high risk of dilution, a Hold recommendation is warranted until initial Phase 1 safety and dosing data are established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.8920%

The Phase 1/2 trial experiences clinical holds or severe adverse events due to metal-modulation toxicity. Capital markets tighten, forcing highly dilutive equity raises at depressed valuations, or clinical development is delayed, exhausting the cash runway before meaningful data is generated.

Base CaseCentral scenario

$1.7550%

Telomir initiates its Phase 1/2 clinical trial for Telomir-Zn in TNBC in late 2026. The company continues to burn cash to fund clinical operations, necessitating further equity dilution via its ATM program or private placements. The stock remains range-bound, closely tracking clinical trial milestones and cash runway updates.

Bull CaseUpside scenario

$2.4030%

The FDA clears the Phase 1/2 trial to proceed smoothly, and early clinical data from the TNBC trial demonstrates exceptional safety and early efficacy signals. Preclinical success in Type 2 diabetes and Wilson's disease translates well, attracting a major pharmaceutical partnership that non-dilutively extends the cash runway.

Scenarios reflect our research view at the research date.

Key Investment Merits

FDA IND clearance secured in April 2026 for lead candidate Telomir-Zn in Triple-Negative Breast Cancer, transitioning the company to clinical-stage.
First-in-class metal-modulating epigenetic mechanism targeting iron-dependent pathways, offering a highly differentiated therapeutic approach.
Broad preclinical pipeline potential with peer-reviewed publications demonstrating efficacy in Wilson's disease and Type 2 diabetes models.

Key Investment Risks

Pre-revenue developmental stage with zero product sales and an accumulated deficit of $41.0 million as of late 2025.
Limited cash runway expected to fund operations only into Q1 2027, presenting high near-term dilution risk.
Inherent high failure rate of early-stage oncology and longevity clinical candidates.

Thesis Invalidation Triggers

Safety-related clinical hold imposed by the FDA on the Phase 1/2 TNBC trial.
Inability to secure additional financing before the end of 2026, threatening going-concern status.
Failure to initiate first-in-human dosing by early 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.